Radioimmunoassay of thyrotrophin releasing hormone in human serum and its clinical application. 1976

T Mitsuma, and Y Hirooka, and N Nihei

A radioimmunoassay for thyrotrophin releasing hormone (TRH) in human serum is described. Inactivation of TRH immunoreactivity by serum is prevented by a mixture of 8-hydroxyquinoline sulphate and Tween 20. This persisted for a long period and at the concentration used in this study did not affect the TRH value. The TRH was extracted from serum with methanol. The results of the recovery experiment, dilution curve of high TRH serum, intra-assay reproducibility and inter-assay variation were quite satisfactory. The lowest detectable amount in this system was 5.0 pg/ml. Immunoreactive TRH levels in the serum were less than 60 pg/ml in normal subjects, were below the limit of detectability in hyperthyroid patients, were 40 to 400 pg/ml in primary hypothyroid patients, were 100 to 600 pg/ml in pituitary hypothyroid patients and below the limit of detectability in hypothalamic hypothyroid patients. In primary hypothyroidism, immunoreactive TRH concentrations in the serum fell to in the normal range during thyroxine substitution. In most cases of hyperthyroidism, immunoreactive TRH concentrations in the serum increased to 5.0 pg/ml or more during antithyroid drug treatment, but in a few cases the level remained below the limit of detectability even though thyroid hormone levels were in the normal range. The above data suggest that this assay system would be a useful tool to study the role of TRH in the hypothalamo-pituitary-thyroid axis.

UI MeSH Term Description Entries
D007031 Hypothalamus Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE. Lamina Terminalis,Preoptico-Hypothalamic Area,Area, Preoptico-Hypothalamic,Areas, Preoptico-Hypothalamic,Preoptico Hypothalamic Area,Preoptico-Hypothalamic Areas
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007553 Isotope Labeling Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labeled substances unless the methods of labeling are substantively discussed. Tracers that may be labeled include chemical substances, cells, or microorganisms. Isotope Labeling, Stable,Isotope-Coded Affinity Tagging,Isotopically-Coded Affinity Tagging,Affinity Tagging, Isotope-Coded,Affinity Tagging, Isotopically-Coded,Isotope Coded Affinity Tagging,Labeling, Isotope,Labeling, Stable Isotope,Stable Isotope Labeling,Tagging, Isotope-Coded Affinity,Tagging, Isotopically-Coded Affinity
D010900 Pituitary Diseases Disorders involving either the ADENOHYPOPHYSIS or the NEUROHYPOPHYSIS. These diseases usually manifest as hypersecretion or hyposecretion of PITUITARY HORMONES. Neoplastic pituitary masses can also cause compression of the OPTIC CHIASM and other adjacent structures. Adenohypophyseal Diseases,Hypophyseal Disorders,Neurohypophyseal Diseases,Anterior Pituitary Diseases,Pituitary Disorders,Pituitary Gland Diseases,Posterior Pituitary Diseases,Adenohypophyseal Disease,Anterior Pituitary Disease,Disease, Adenohypophyseal,Disease, Anterior Pituitary,Disease, Neurohypophyseal,Disease, Pituitary,Disease, Pituitary Gland,Disease, Posterior Pituitary,Diseases, Adenohypophyseal,Diseases, Anterior Pituitary,Diseases, Neurohypophyseal,Diseases, Pituitary,Diseases, Pituitary Gland,Diseases, Posterior Pituitary,Disorder, Hypophyseal,Disorder, Pituitary,Disorders, Hypophyseal,Disorders, Pituitary,Hypophyseal Disorder,Neurohypophyseal Disease,Pituitary Disease,Pituitary Disease, Anterior,Pituitary Disease, Posterior,Pituitary Diseases, Anterior,Pituitary Diseases, Posterior,Pituitary Disorder,Pituitary Gland Disease,Posterior Pituitary Disease
D011136 Polysorbates Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals. Polysorbate,Polysorbate 20,Polysorbate 80,Sorbitan Derivatives,Tween,Tweens,PSML,Polyoxyethylene Sorbitan Monolaurate,Tween 20,Tween 60,Tween 80,Tween 81,Tween 85,20s, Polysorbate,20s, Tween,60s, Tween,80s, Polysorbate,80s, Tween,81s, Tween,85s, Tween,Derivative, Sorbitan,Derivatives, Sorbitan,Monolaurate, Polyoxyethylene Sorbitan,Monolaurates, Polyoxyethylene Sorbitan,PSMLs,Polyoxyethylene Sorbitan Monolaurates,Polysorbate 20s,Polysorbate 80s,Sorbitan Derivative,Sorbitan Monolaurate, Polyoxyethylene,Sorbitan Monolaurates, Polyoxyethylene,Tween 20s,Tween 60s,Tween 80s,Tween 81s,Tween 85s
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002606 Charcoal An amorphous form of carbon prepared from the incomplete combustion of animal or vegetable matter, e.g., wood. The activated form of charcoal is used in the treatment of poisoning. (Grant & Hackh's Chemical Dictionary, 5th ed) Activated Charcoal,Actidose,Actidose-Aqua,Adsorba,Carbomix,Charbon,CharcoAid,CharcoCaps,Charcodote,Formocarbine,Insta-Char,Kohle-Compretten,Kohle-Hevert,Kohle-Pulvis,Kohle-Tabletten Boxo-Pharm,Liqui-Char,Norit,Ultracarbon,Charcoal, Activated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000432 Methanol A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness. Alcohol, Methyl,Carbinol,Sodium Methoxide,Wood Alcohol,Alcohol, Wood,Methoxide, Sodium,Methyl Alcohol

Related Publications

T Mitsuma, and Y Hirooka, and N Nihei
October 1973, The Journal of endocrinology,
T Mitsuma, and Y Hirooka, and N Nihei
November 1974, Acta endocrinologica,
T Mitsuma, and Y Hirooka, and N Nihei
February 1981, European journal of nuclear medicine,
T Mitsuma, and Y Hirooka, and N Nihei
February 1974, Nihon Naibunpi Gakkai zasshi,
T Mitsuma, and Y Hirooka, and N Nihei
January 1971, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
T Mitsuma, and Y Hirooka, and N Nihei
January 1975, Gerontologia clinica,
T Mitsuma, and Y Hirooka, and N Nihei
March 1971, British medical journal,
T Mitsuma, and Y Hirooka, and N Nihei
November 1977, Acta endocrinologica,
T Mitsuma, and Y Hirooka, and N Nihei
September 1969, Nihon Naibunpi Gakkai zasshi,
T Mitsuma, and Y Hirooka, and N Nihei
January 1987, Hormone and metabolic research. Supplement series,
Copied contents to your clipboard!